Close

Aduro Biotech (ADRO) Will Present Strong ADU-5100 Preclinical Data at ESMO Symposium

Go back to Aduro Biotech (ADRO) Will Present Strong ADU-5100 Preclinical Data at ESMO Symposium

Aduro Biotech Presents Preclinical Data Demonstrating Acute and Systemic Immune Activation through STING Pathway Stimulation with ADU-S100

November 7, 2016 8:00 AM EST

BERKELEY, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (Nasdaq: ADRO) today highlighted an oral presentation given by the companys chief scientific officer, Thomas Dubensky Jr., Ph.D., at the 4th European Society of Medical Oncology (ESMO) Symposium on Immuno-Oncology held last week in Lausanne, Switzerland.  The data, generated from multiple preclinical models, demonstrated important changes in the tumor microenvironment and the activation of acute and systemic tumor-specific immune cell responses following intratumoral administration of ADU-S100 (also known as MIW815), an investigational STING (Stimulator of Interferon Genes) Pathway Activator immunotherapy.  Importantly, these... More